CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 607 enrolled
Drug / intervention
Sirolimus-eluting stent +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00133237
NCT00133237Phase 4Completed
CompareCT.gov

Prospective, Randomized Trial of the Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent for the Treatment of Unprotected Left Main Coronary Artery Disease(ISAR-LEFT-MAIN)

Deutsches Herzzentrum Muenchen·interventional·Posted Aug 23, 2005·Updated Mar 15, 2010

In Brief

A Phase 4 clinical trial evaluating Sirolimus-eluting stent and Paclitaxel-eluting stent for Coronary Disease. Completed, enrolled 607 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy of sirolimus- and paclitaxel-eluting stents for treatment of unprotected left main coronary artery disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Disease
CountriesGermany
CollaboratorsTechnical University of Munich

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 23, 2005
Enrollment StartJul 1, 2005
Primary CompletionJun 1, 2008
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 20.9 years ago

Interventions

Sirolimus-eluting stentdevice

cypher stent is implanted due to randomization.

Paclitaxel-eluting stentdevice

taxus stent is implanted due to randomization.